Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on ...
Biotech royalty player Ligand Pharmaceuticals reported a notable insider sale following a year of strong stock performance.
View Ligand Pharmaceuticals Incorporated LGND stock quote prices, financial information, real-time forecasts, and company news from CNN.
This sell reduced Ligand Pharmaceuticals from 5.8% to 4.8% of Ashford Capital Management’s 13F reportable AUM. Top holdings after the filing: NASDAQ:GSAT: $51.3 million (5.7% of AUM) NASDAQ:LGND: ...
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor ...
JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc has received approval from the U.S. Food and Drug Administration ...
Ligand Pharmaceuticals (LGND) is a royalty investor in late-stage biopharma, with revenue and EPS growth driven by a robust portfolio. LGND expects royalty revenue to compound at a 23% CAGR through ...
Royalties surged to $43.0 million in the first quarter of 2026, a 56% year-over-year increase that underpinned the bullish narrative on the call. Management credited the growth to momentum from key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results